Xeltis is among seven European companies selected to join the prestigious research network ArtMoMa. The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. ArtMoMa is built on synergies and complementarities between [...]
Deutsche - Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve patients’ lives at the Spirit of Bern conference on 27th February. The Xeltis technology enables patients that [...]
For more on the data, please click here CEO announced continuation of the clinical trial program for the pulmonary valve in EU, Asia and USA Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves [...]
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The funding was provided by existing institutional and private investors, including all venture capital funds (VCs) already financing the company. [...]
